Want to see AU:IDT full AI Analyst Report?
Top Page
IDT Australia Limited
(Sydney:IDT)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.04
▼(-28.00% Downside)
Action:Upgraded
Date:07/23/26
The score is weighed down primarily by weak financial performance—ongoing losses, declining/negative margins, and negative operating/free cash flows. Technical indicators are also generally bearish with the stock below longer-term moving averages and a negative MACD, though oversold signals may limit near-term downside. Valuation is constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
CDMO fee-for-service model
A fee-for-service CDMO model provides durable, contract-driven revenue from both manufacturing and development services. This bifurcated revenue base supports predictable client workstreams, aligns cash generation to customer projects and limits single-product commercial risk over the medium term.
Negative Factors
Ongoing negative profitability
Sustained negative net profit and EBIT margins erode retained capital and constrain the company’s ability to reinvest in capacity or R&D. Persistent unprofitability increases reliance on external funding and weakens resilience to market or cost shocks over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
CDMO fee-for-service model
A fee-for-service CDMO model provides durable, contract-driven revenue from both manufacturing and development services. This bifurcated revenue base supports predictable client workstreams, aligns cash generation to customer projects and limits single-product commercial risk over the medium term.
Read all positive factors
IDT Australia Limited (IDT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$15.62M
Dividend YieldN/A
Average Volume (3M)336.94K
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue Growth6.14%
EPS Growth-20.00%
CountryAU
Employees156
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.01
Shares Outstanding427,261,570
10 Day Avg. Volume373,970
30 Day Avg. Volume336,941
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)1.73
Price to Sales (P/S)1.92
P/FCF Ratio-5.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)AU$32.00M
IDT Australia Limited Business Overview & Revenue Model
Company Description
IDT Australia Limited is an enterprise deeply involved in the entire lifecycle of pharmaceutical products, from initial research and development through to manufacturing and global distribution of both active pharmaceutical ingredients (APIs) and ...
How the Company Makes Money
IDT makes money primarily by providing fee-for-service pharmaceutical manufacturing and related technical services to third-party customers. Key revenue streams include (1) contract manufacturing revenues from producing finished pharmaceutical pro...
IDT Australia Limited Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.00M | 19.77M | 13.23M | 6.93M | 12.11M | 15.99M |
| Gross Profit | 7.10M | 9.69M | 10.42M | -3.53M | 2.82M | 4.88M |
| EBITDA | -4.11M | -6.54M | -5.56M | -8.83M | -340.00K | 2.75M |
| Net Income | -6.13M | -8.06M | -5.41M | -8.50M | -1.16M | 2.10M |
Balance Sheet | ||||||
| Total Assets | 34.55M | 36.92M | 31.37M | 28.29M | 30.08M | 34.13M |
| Cash, Cash Equivalents and Short-Term Investments | 1.93M | 4.11M | 904.00K | 4.43M | 9.21M | 6.93M |
| Total Debt | 9.86M | 10.40M | 4.47M | 740.00K | 881.00K | 766.00K |
| Total Liabilities | 14.23M | 15.03M | 7.93M | 4.15M | 3.46M | 6.51M |
| Stockholders Equity | 20.31M | 21.89M | 23.44M | 24.14M | 26.63M | 27.61M |
Cash Flow | ||||||
| Free Cash Flow | -885.00K | -7.55M | -10.30M | -8.42M | 1.95M | -156.00K |
| Operating Cash Flow | 609.00K | -6.25M | -9.60M | -7.90M | 2.86M | 370.00K |
| Investing Cash Flow | -3.19M | -4.50M | -1.09M | -522.00K | -912.00K | -526.00K |
| Financing Cash Flow | 3.46M | 10.75M | 6.77M | 3.64M | 337.00K | 224.00K |
IDT Australia Limited Technical Analysis
Positive
0.05
Price Trends
0.03
Positive
0.04
Positive
0.04
Negative
Market Momentum
<0.01
Negative
58.93
Neutral
93.33
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDT, the sentiment is Positive. The current price of 0.05 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and above the 200-day MA of 0.04, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.93 is Neutral, neither overbought nor oversold. The STOCH value of 93.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IDT.
IDT Australia Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | AU$132.67M | 13.12 | 19.15% | 4.33% | 17.31% | 17.99% | |
55 Neutral | AU$61.27M | -16.09 | -1.67% | ― | 15.21% | -141.82% | |
54 Neutral | AU$51.82M | -117.95 | -0.79% | ― | 6.80% | 98.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | AU$4.15M | 0.22 | 93.89% | ― | -29.95% | ― | |
42 Neutral | AU$20.02M | -5.07 | 4388.00% | ― | -53.90% | 57.52% | |
41 Neutral | AU$15.62M | -2.66 | -29.05% | ― | 6.14% | -20.00% |
* Healthcare Sector Average
AU:IDT
IDT Australia Limited
0.04
-0.03
-43.24%
AU:CAN
Cann Group
0.01
>-0.01
-28.57%
AU:VLS
Vita Life Sciences Limited
2.50
0.40
19.05%
AU:LGP
Little Green Pharma Ltd.
0.08
-0.03
-30.91%
AU:MVP
Medical Developments International Limited
0.48
-0.24
-33.33%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-22.73%
IDT Australia Limited Corporate Events
IDT Australia Trims Capital Base as Conditional Rights Lapse
Jul 28, 2026
IDT Australia Limited has notified the market of a change in its issued capital following the cessation of certain securities. The company reported that 164,000 ordinary fully paid shares have lapsed after conditional rights attached to these secu...
IDT Australia Director Geoffrey Sam Increases Indirect Shareholding
May 6, 2026
IDT Australia Limited has reported a change in the interests of director Geoffrey Sam, who has increased his indirect holding in the company through family-related entities. The transactions, conducted via on-market trades on 30 April 2026 at pric...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.